Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQUIP
NCT07466498Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of DehydraTECH-estrogen in prostate cancer (PCa) (2 cohorts), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Change in mean daily hot flash score at 12 weeks. Planned start Dec 2026; status: recruiting.
02
Drugs
DehydraTECH-estrogen
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07466498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07466498.